Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less than 6%. Chronic pancreatitis (CP), an inflammatory process in of the pancreas, is a strong risk factor for PDAC. Several genetic polymorphisms have been discovered as susceptibility loci for both CP and PDAC. Since CP and PDAC share a consistent number of epidemiologic risk factors, the aim of this study was to investigate whether specific CP risk loci also contribute to PDAC susceptibility. We selected five common SNPs (rs11988997, rs379742, rs10273639, rs2995271 and rs12688220) that were identified as susceptibility markers for CP and analyzed them in 2,914 PDAC cases, 356 CP cases and 5,596 controls retrospectively collected in the context of the international PANDoRA consortium. We found a weak association between the minor allele of the PRSS1-PRSS2-rs10273639 and an increased risk of developing PDAC (OR homozygous 5 1.19, 95% CI 1.02-1.38, p 5 0.023). Additionally all the SNPs confirmed statistically significant associations with risk of developing CP, the strongest being PRSS1-PRSS2-rs10273639 (OR heterozygous 5 0.51, 95% CI 0.39-0.67, p 5 1.10 3 10 26 ) and MORC4-rs 12837024 (OR homozygous 5 2.07
(1.55-2.77, p trend 5 0.7 3 10 211 ). Taken together, the results from our study do not support variants rs11988997, rs379742, rs10273639, rs2995271 and rs12688220 as strong predictors of PDAC risk, but further support the role of these SNPs in CP susceptibility. Our study suggests that CP and PDAC probably do not share genetic susceptibility, at least in terms of high frequency variants.
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of <6%. 1 Although PDAC is still a relatively rare disease, it is predicted to become the second leading cause of cancer death within the next decade. 2 Compared to other cancer types, only a small number of epidemiologic risk factors have been established including cigarette smoking, heavy alcohol consumption, obesity and family history of pancreatic cancer. [3] [4] [5] A rather small number of genetic polymorphisms have also an impact on the disease susceptibility. These risk variants have been identified through genome-wide association studies (GWAS) and/ or large candidate gene association studies. [6] [7] [8] [9] [10] [11] [12] [13] [14] More recently also leukocyte telomere length has been investigated as a pancreatic cancer risk factor. [15] [16] [17] In addition, new onset diabetes mellitus diagnosed at least 3 years before diagnosis of pancreatic cancer or chronic pancreatitis (CP) are among the strongest risk factors for PDAC. 18, 19 CP is an inflammatory condition of the pancreas characterized by pain, chronic inflammation and other complications, such as pseudocysts. [20] [21] [22] Several risk factors have been identified for CP including environmental and genetic predisposing highpenetrance loci. 21, 23 Whitcomb and colleagues have also identified through a GWAS a small number of high-frequency, low-penetrance susceptibility loci for CP. 24 Several life-style risk factors are shared between CP and PDAC such as cigarette smoking and heavy alcohol drinking, nonetheless no one has attempted to link the genetic background of CP to PDAC. In this study, we tried to fill this gap and expand our What's new? Do pancreatic cancer and chronic pancreatitis share common genetic risk factors? Probably not, according to new results. Because chronic pancreatitis is a risk factor for pancreatic ductal adenocarcinoma, these authors wondered whether the same genetic loci paved the way for both conditions. Using genotypes from almost 3,000 cancer patients, they investigated five common polymorphisms associated with chronic pancreatitis risk. They found that none of them strongly predicted pancreatic cancer.
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knowledge on the genetic basis of PDAC. To accomplish our goal we have used 2,914 PDAC patients and 5,596 controls in the context of the international PANcreatic Disease ReseArch (PANDoRA) consortium 25 and we have genotyped them for five GWAS-identified CP susceptibility single nucleotide polymorphisms (SNPs). As a secondary aim we have also used 356 sporadic CP cases and the same set of controls to replicate the GWAS findings.
Material and Methods

Study population
The PANDoRA consortium has been described in detail elsewhere. 25 For this particular study 3,165 PDAC cases, 356 sporadic CP cases and 5,787 controls were retrospectively collected from nine countries (Italy, Greece, Germany, Czech Republic, United Kingdom, Lithuania, Poland, Netherlands and Japan). Table 1 summarizes the study population. Cases were defined by a confirmed diagnosis of PDAC or CP. Controls were recruited in the same centers or geographical area where the cases were recruited. British and Dutch controls (N 5 176 and 102, respectively) were selected from healthy volunteers recruited from the general population in the European Prospective Investigation on Cancer (EPIC), an ongoing prospective cohort being carried out in ten European countries. 26 All subjects provided written informed consent and the study was approved by Ethical Review Board of the University of Heidelberg (Medizinische Fakult€ at Heidelberg). The study was performed in accordance with the Declaration of Helsinki.
SNP selection
We have selected five common SNPs that were identified as susceptibility markers for CP by Whitcomb and collaborators through a GWAS (20) . We have also consulted the GWAS catalogue (https://www.ebi.ac.uk/gwa) to ascertain if there were additional common risk alleles for CP but we did not find any. Specifically, we selected: MUM1-like 1 (MUM1L1-CXorf57)-rs379742 on chromosome X (Xq22.3), Protease, Serine 1/2 (PRSS1-PRSS2)-rs10273639 on chromosome 7 (7q34), KIAA1462-mitochondrial poly(A) polymerase (MTPAP)-rs2995271 on chromosome 10 (10p11.23), sterile alpha motif domain containing 12 -TNF receptor superfamily member 11b (SAMD12-TNFRSF11B)-rs11988997 on chromosome 8 (8q24) and Claudin 2 (CLDN2)-rs12688220 on chromosome X (Xq22.3-q23). The genotyping for this latter SNP did not work and therefore we used a proxy: MORC family CW-type zinc finger 4 (MORC4)-rs12837024 that is in tight linkage disequilibrium (r 2 5 0.951 in HapMap release 21).
Sample preparation and genotyping
DNA was extracted from blood using a QiaCube HT instrument in batches of 96 samples, using QIAampV R 96 DNA kit. The DNA samples were quantified using a NanoDrop instrument and stored at 2208C until usage. Genotyping was performed with TaqMan (ABI, Applied Biosystems, Foster City, CA) technology using 384-well plates. Detection was done with a Viia7 instrument and Viia7 software (Applied Biosystems, Foster City, CA). The order of cases and controls was randomized in the genotyping plates in order to avoid plates of only cases or only controls. The status (PDAC case, CP case or control) of each sample was unknown to the person performing the genotyping. To ensure the quality of the genotyping, 10% of all the samples were duplicated, introduced in the plates, and genotyped at the same time as the regular samples. The concordance rate between the samples and their duplicates was checked after genotyping. Genotyping for Dutch and British controls was performed in the context of a GWAS using the Human 660W-Quad BeadChip array according to manufacturer's instructions (Illumina, San Diego, CA).
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) was checked in the control subjects of the study for each country separately. To assess the effect of the polymorphic variant on the risk of developing PDAC and CP we used an unconditional logistic regression calculating odds ratios (OR), 95% confidence intervals (95% CIs) and p values. We used a co-dominant model of inheritance and the more frequent allele in the controls was set as the reference. The Caucasian and Japanese populations were kept separate in the analysis. All analyses were adjusted for age, gender and geographic origin (in the Caucasians). We also performed a stratified analysis by country.
Results
Quality control and data filtering
All polymorphic variants were in HWE, with the exception of MORC4-rs12837024 in one of the Italian centers (Padua). The samples from Padua were therefore excluded from the association analysis for this particular SNP. A total of 442 subjects (251 PDAC cases and 191 controls) were removed after genotyping because they had a call rate <75%. After the removal of these subjects the average SNP call rate was 94.43% with a minimum of 90.84% (rs12837024) and a maximum of 96.12% (rs11988997). The quality control analysis showed a concordance rate of 99.29% between the duplicate samples. After exclusions, 2,914 PDAC cases, 356 CP cases and 5,596 controls were used for statistical analyses.
Effect of the SNPs on PDAC susceptibility
In the Caucasian population, we found that the carriers of the minor allele of PRSS1-PRSS2-rs10273639 had an increased risk of developing PDAC (OR heterozygous 5 1.13, 95% CI 1.01-1.27, p 5 0.039, and OR homozygous 5 1.19, 95% CI 1.02-1.38, p 5 0.023). We did not observe any statistically significant association for the other selected SNPs. The results of these analyses are shown in Table 2 . We also performed stratified analyses considering the different countries separately but we did not observe any statistically significant association (data not shown). For the Japanese population, we observed no statistically significant association (Table 3) .
Effect of the SNPs on CP susceptibility
All selected SNPs were associated with chronic pancreatitis except for KIAA1462-MTPAP-rs2995271. ). The results of these analyses are shown in Table 4 .
Discussion
Pancreatic cancer and chronic pancreatitis share several risk factors such as cigarette smoking and heavy alcohol use, but less is known about any possible link between the risk alleles of these two diseases. Furthermore, CP is considered a risk factor for PDAC. Considering the importance of identifying novel genetic susceptibility markers for PDAC we have investigated whether GWAS-identified susceptibility SNPs for CP are also PDAC susceptibility loci. Linking CP and PDAC from a genetic standpoint would be an extremely useful tool for identifying CP patients at risk of developing PDAC. We have selected five SNPs that have been studied and validated in CP 24, [27] [28] [29] and tested these in a large case-control study, comprising almost 3,000 PDAC cases and 5,000 controls in the context of the international PANDoRA consortium. Our results do not suggest a strong effect of these five selected SNPs in PDAC susceptibility, although one of the variants, PRSS1-PRSS2-rs10273639, showed a tendency of increasing the disease risk in the carriers of the minor allele (p 5 0.023). Numbers may not add up to the total of available subjects due to genotyping failure. 
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Campa et al. Table 3 . Association between the selected SNPs and PDAC in the Japanese population Numbers may not add up to the total of available subjects due to genotyping failure. 3 OR: odds ratio; CI: confidence interval. All analyses were adjusted by age and sex. 4 Codominant model of inheritance the p value is referred to Mm vs. MM. Numbers may not add up to the total of available subjects due to genotyping failure. We have also used a relatively small set of CP patients to test the association in our population and we observed statistically significant associations for all the SNPs with the exception of KIAA1462-MTPAP-rs2995271. For all the polymorphisms, the risk allele was the same as the one identified in the original publication, confirming once more the involvement of the selected variants in CP susceptibility. For KIAA1462-MTPAP-rs2995271 the most likely cause of our inability to replicate the finding is the lack of statistical power (<76%) when considering only CP cases. The association between PRSS1-PRSS2-rs10273639 and PDAC risk is interesting given the importance of the gene in pancreas physiology and function. The PRSS1/2 genes encode the cationic trypsinogen and anionic trypsinogen, respectively, two digestive enzymes produced by the acinar cell of the pancreas. The premature activation of the enzymes increases the risk of developing pancreatitis. Several genetic variants, with low and high penetrance have been identified in the locus to increase or decrease the susceptibility do develop the disease. 21, 24, [30] [31] [32] The general consensus is that gain of function mutations and polymorphisms increase the risk while loss of function decrease the risk. The minor allele of the variant identified through the GWAS is thought to decrease the production of trypsinogen and indeed in the original GWAS and in our results it shows a reduction in the risk of developing CP. However, our results on PDAC seem to suggest the opposite, that is, an increase in risk for the minor allele. It is difficult to explain this finding, however it is mirrored by all the other SNPs that, even if not significant, seem to have an opposite effect on PDAC susceptibility compared with CP susceptibility. This could suggest different mechanisms in the etiology of the two diseases or, more simply, that our results are due to statistical fluctuation imputable to the capricious nature of genetic associations. Additionally, if correcting for multiple testing using the Bonferroni method the association does not show statistical significance any more.
In another recent GWAS, Weiss and colleagues have identified the fucosyltransferase 2 (FUT2) 33 and the ABO blood group as a potential risk factor for CP, however we decided not to genotype those SNPs in PDAC cases and controls since ABO is a well known susceptibility locus 6,11-13 while FUT2 polymorphisms do not seem to play a major role in PDAC etiology. 13 One obvious strength of this study is its size that, with almost 3,000 cases and 5,000 controls, is one of the largest studies on PDAC susceptibility. Considering the ORs and minor allele frequency in the original report we had >93% power to detect the associations of the CP loci in PDAC, with an alpha set to 0.01 to consider multiple comparisons. A possible limitation of the study is the fact that we cannot clinically characterize the CP patients enrolled in the study, as we do not have any information whether the pancreatitis was of idiopathic, alcoholic or hereditary origin, however, the selected SNPs do replicate in PANDoRA CP patients, highlighting the importance of those loci in the disease etiology. Another limitation is the fact that we did not cover the rare variants of SPINK, CFTR, CTRC that are associated with high penetrance to CP risk, and therefore we cannot exclude that those variants might be involved in PDAC risk.
In conclusion, we have confirmed a role for rs379742, rs10273639, rs2995271 and rs12688220 (though the use of rs12837024 as a proxy) as susceptibility loci for CP and we can exclude a major overlap of common (i.e., loci with high frequency in the general population) susceptibility loci (not considering ABO) between PDAC and CP.
